T0	KEYPHRASE_NOTYPES 20 39	pharmacyte approach
T1	KEYPHRASE_NOTYPES 84 95	ACT T-cells
T2	KEYPHRASE_NOTYPES 177 200	duration of stimulation
T3	KEYPHRASE_NOTYPES 274 294	cell-bound particles
T4	KEYPHRASE_NOTYPES 317 330	cell division.
T5	KEYPHRASE_NOTYPES 394 401	T-cells
T6	KEYPHRASE_NOTYPES 655 689	elimination of large tumor burdens.
T7	KEYPHRASE_NOTYPES 711 718	T-cells
T8	KEYPHRASE_NOTYPES 789 848	targeted particles, allowing adoptively-transferred T-cells
T9	KEYPHRASE_NOTYPES 1093 1124	target nanoparticles to T-cells
T10	KEYPHRASE_NOTYPES 1159 1177	studies, particles
T11	KEYPHRASE_NOTYPES 1195 1202	T-cells
T12	KEYPHRASE_NOTYPES 1240 1265	specific T-cell receptors.
T13	KEYPHRASE_NOTYPES 1276 1316	peptide-MHC-functionalized nanoparticles
T14	KEYPHRASE_NOTYPES 1388 1405	T-cells [18,19] â€”
T15	KEYPHRASE_NOTYPES 1425 1449	treating graft rejection
T16	KEYPHRASE_NOTYPES 1500 1520	cancer immunotherapy.
